Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Email Antibe and Demand CEO be Fired!!

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 11, 2021 10:15pm

183 Views

Post# 32782733

RE:RE:RE:RE:RE:Email Antibe and Demand CEO be Fired!!

That's exactly it JimmyJ.
Win or lose.
Been holding on to my 15-17 cent shares ($1.50 to $1.70) since 2017 ... win or lose.

The only thing I see happening (like P2B) is a run up as we prep and start P3.
We will likely have exciting moments in the run to the end of P3 as well.
Then the fear sets in about what the results actually tell us.

I'm hoping that somewhere before the results, we've made some big partnership moves on OTENA (at a minimum)

To be determined.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects